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Introduction: Long-term smoking cessation success rates without substantive intervention 
remain abysmal. Some studies suggest an association between sociodemographic factors and 
tobacco cessation success. We sought to explore US adult tobacco users’ willingness-to-try 
diverse tobacco cessation methods by sociodemographics and tobacco use habits. 
Methods: We electronically surveyed a convenience sample of 562 US adults to explore 
willingness-to-try various cessation methods among those who reported current tobacco cigarette 
use. Participants rated their willingness-to-try different cessation methods. Logistic regression 
models examined associations between willingness-to-try tobacco cessation methods based on 
sociodemographic and tobacco use characteristics. 
Results: Non-whites were more likely to report willingness-to-try counseling (RR 1.32, 95% CI 
1.14, 1.52) and those with high school education or less were less likely to report willingness-to-
try counseling (RR 0.78, 95% CI 0.64, 0.95). Those with lower income were less likely to report 
willingness-to-try any medication (RR 0.84, 95% CI 0.73, 0.98). High nicotine dependence was 
associated with a high likelihood of reporting willingness-to-try any evidence-based method (RR 
1.07, 95% CI 1.04, 1.10) and a history of quit attempts was associated with likelihood to report 
willingness-to-try any evidence-based method (RR 1.31, 95% CI 1.10, 1.56). 
Conclusion: Sociodemographics and nicotine dependence may affect preferences for tobacco 












Smoking accounts for an estimated 6 million deaths every year globally. By 2030, the 
mortality rate is expected to increase to approximately 8 million deaths annually[1-3]. According 
to the 2016 National Health Interview Survey, up to 15.5% of adults in the US smoke cigarettes, 
an improvement from 20.9% in 2005 [4]. The success rate of smoking cessation ranges from 5 - 
7.4 % [5-7]. Evidenced-based methods are less frequently used than non-evidence-based 
methods,[8] yet studies have shown that treatment with pharmacotherapy and counseling 
support, either individually or when combined together, increase the likelihood of success by 
greater than 10% [9,10].  
There is considerable variability among people who smoke in terms of smoking cessation 
methods used and successful quitting [11,12]. In the 2010 National Health Interview Survey, low 
income and non-Hispanic blacks indicated a higher interest in smoking cessation than non-
Hispanic whites but had lower rates of success [13,14]. In a separate study, Hispanics were half 
as likely to seek assistance with tobacco cessation compared with whites and heavy smokers 
were more likely to seek assistance compared with light smokers [11]. Tobacco users who smoke 
more than 19 cigarettes per day have been found to have a higher likelihood of success with 
smoking cessation while electronic nicotine delivery system (ENDS) users are associated with 
lower likelihood of smoking cessation success [12].  
Gaps exist in the understanding of different subgroups of tobacco users’ willingness-to-
try tobacco cessation methods including counseling and pharmaceutical products [15]. 
Identifying effective strategies for tobacco cessation, integrated with patients’ preferences 
especially in a sociodemographically diverse setting, is beneficial and may lead to a reduction in 
tobacco-related morbidity and mortality [16]. The current study examines a convenience sample 
of U.S. adult tobacco users’ self-report of their willingness-to-try various forms of evidence-
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based and non-evidence-based cessation methods. Our study investigates whether differences in 
participants’ preferences of tobacco cessation methods is associated with sociodemographic and 
tobacco use factors. 
 
MATERIALS AND METHODS 
Design 
We conducted a cross-sectional online survey of various tobacco cessation methods. The study 
included a pre-test phase using an academic email system. Twelve individuals participated in the 
pretesting of the survey between May 9th and May 14th, 2016. We revised and simplified the 
language of the survey based on feedback from the pretest phase. To improve the clarity of the 
survey, we carried out a second round of testing with 75 participants who were recruited from a 
survey panel via Research Now, a market research group, between August 15th and 16th, 2016. 
After this round of testing, we revised the survey language again and fielded the final version of 
the survey between August 26th and August 31st, 2016. Participants from the Research Now 
panel were compensated per the marketing group’s rates at the time. This study was approved by 
the UNC Chapel Hill School of Medicine Institutional Review Board. 
Sample 
The team enlisted and enrolled 900 participants, aged 18 and older, who were members of an 
online survey panel of a market research group - Research Now. The current analysis was limited 
to 562 participants who reported current tobacco cigarette use—defined as use in the past 30 
days. Participants who reported ENDS use within the last 30 days in addition to tobacco cigarette 
use were also included in the study. Participants who reported current ENDS use were classified 
as dual users. All participants had to live in the United States and able to complete an online 
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survey in English. Research Now does not provide data on how many people receive the initial 
invitation to participate in a study, thus we cannot report a response rate.  
Measures 
Data on sociodemographic characteristics collected included questions about race, education 
level and yearly household income. The survey also collected details about each participant’s 
tobacco use characteristics including number of cigarettes per day, time to first smoke after wake 
and past attempts to quit. The heaviness of smoking index (HSI) which estimates the level of 
nicotine dependence as mild, moderate and high based on the number of cigarettes smoked per 
day and time to first smoke after waking was calculated for each participant [17].  
Outcome Measures 
Participants were asked to rate their willingness-to-try different forms of evidence-based and 
non-evidenced-based tobacco cessation methods. Response options included “would definitely 
use”, “likely to try”, “unlikely to try” and “would definitely not try”. Evidence-based methods 
listed were medications including nicotine containing products, wellbutrin/zyban and chantix, 
and different forms of counseling support, including individual counseling, support group or 
class, telephone quitline, online program, texting program and any counseling. Non evidenced-
based methods included forms of complementary and alternative therapy, other tobacco or 
nicotine delivery systems and quitting without any assistance. Participants were not informed of 
which methods are evidence-based or non-evidence-based.  
 
Analysis 
The analytical sample contained only current tobacco cigarette users and dual users. Some 
sociodemographic variables were dichotomized. Race was collapsed into non-white and white 
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and race was not further classified by ethnicity due to the low number of Hispanic participants. 
Education was classified as high school degree/GED or less and some college or higher and 
income was classified as less than $30,000 and $30,000 or greater. HSI was further dichotomized 
into high or moderate/low while quit attempts in the past year and ENDS use was categorized as 
yes or no. Positive responses for the use of tobacco cessation methods - “will definitely use” and 
“likely to try” - were categorized as willingness-to-try for the analysis.  
Bivariate associations between ENDS use (yes/no) and baseline characteristics (i.e. 
sociodemographic characteristics and tobacco use characteristics) were examined using t-tests 
for normally distributed continuous variables, Wilcoxon-Mann-Whitney tests for non-parametric 
continuous variables, and Chi-square tests for categorical variables. Unadjusted and adjusted 
effects were estimated for willingness-to-try cessation methods using logistic regression. 
Purposeful selection method was used [18] to determine variables to include in adjusted models, 
which involved an iterative process of examining all covariates as potential significant predictors 
or confounders. In the iterative process, covariates were removed from the model if they were 
non-significant at alpha=0.1 and not a confounder (i.e., did not result in a parameter estimate 
change greater than 15%). The final model included only significant covariates and confounder. 
Data were analyzed using SAS version 9.4 (SAS Institute, Inc.) with a two-tailed significance 
level (p<.05). Risk ratios are reported rather than odds ratios because the outcome events are 
relatively common (incidence of more than 10%) and thus risk ratios offer more appropriate 
approximations [19].  
RESULTS 
From the larger sample of 900 participants who completed the survey, a total of 562 were 
tobacco cigarette or dual users. Mean age was 47 years. Most participants were white (82%), 
47% were female and 76% had a college education or higher. Approximately 24% of participants 
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had an annual household income of less than $30,000. Of this sample, 88% reported smoking 
less than 20 cigarettes per day, 14% reported less than 5 minutes to first smoke after wake and 
6.2% had a high HSI score. Eighty-three percent reported making an attempt to quit smoking in 
the past year and almost half (48%) were dual users.(Table 1) 
Adjusted logistic regression analysis showed that non-white participants were more likely 
to report willingness-to-try any counseling method (RR 1.32, 95% CI 1.14, 1.52) compared to 
whites and participants with a high school education or less were less likely to report 
willingness-to-try any counseling method compared with those with a college education or 
higher (RR 0.78, 95% CI 0.64, 0.95). Participants with an annual income of less than $30,000 
were less likely to report willingness-to-try any medication (RR 0.84, 95% CI 0.73, 0.98) and 
any counseling ( RR 0.82, 95% CI 0.67, 0.99) when compared with participants with higher 
annual income.  
Participants with a high HSI score were more likely to report willingness-to-try any 
medication, any counseling and any evidenced-based method (RR 1.07, 95% CI 1.04, 1.10) and 
less likely to report willingness-to-try cold turkey (RR 0.90, 95% CI 0.87, 0.94). Those who had 
attempted to quit in the past were also more likely to report willingness-to-try any medication, 
any counseling and any evidenced-based method (RR 1.31, 95% CI 1.10, 1.56) compared with 
those with no history of quit attempts. Although, dual users were more likely to report 
willingness-to-try any counseling and any evidenced-based method compared with tobacco 
cigarette only users, these associations lost statistical significance after adjusting for other 
variables in the final model (Table 2). 
Table 3 represents a breakdown of comparison of willingness-to-try different tobacco 
cessation methods among tobacco cigarettes only users and dual users. Dual users were more 
likely to report a willingness-to-try wellbutrin when compared with tobacco-only users with 
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similar non-significant trends for other medications (41% vs 30%; p value = 0.005). Dual users 
were significantly more likely to report willingness-to-try any type of counseling support listed, 
except for individual counseling, which did not reach statistical significance. Overall, dual users 
were more likely to report a willingness-to-try any evidence-based method compared with 
tobacco cigarette only users (82% vs 73%; p= 0.01). Dual users were also more likely to report 
willingness-to-try non-evidenced-based methods including different forms of complementary 
and alternative methods and other tobacco or nicotine delivery systems.  
 
DISCUSSION 
The current study explores a convenience sample of tobacco users’ willingness-to-try different 
tobacco cessation methods by sociodemographics and level of nicotine dependence. Our findings 
reveal that preferences for tobacco cessation methods exist based on race/ethnicity, level of 
income, education and severity of nicotine dependence. While non-white participants were 
significantly more likely to report willingness-to-try counseling over other cessation methods, 
those with lower education level were less likely to report willingness-to-try counseling and 
those with an annual household income of less than $30,000 were less likely to report 
willingness-to-try any medication. Participants with a higher HSI, higher tobacco dependency, 
were more likely to report willingness-to-try any evidence-based cessation method over non-
evidence-based methods. The data also indicates that dual users were more likely to report 
willingness-to-try any evidenced-based method compared with tobacco cigarette only users. 
  Our results have implications for public health practice, primary care clinician counseling 
services and future research. Our finding that non-white participants had a higher likelihood to 
report willingness-to-try counseling compared with whites is similar to previous studies that 
show a higher utilization of quitlines, telephone counseling, by non-whites compared with white 
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tobacco users in studies to assess for variations in quitline reach by ethnicity and race [20,21]. 
This preference for counseling over other methods may arise from lack of knowledge or 
awareness about pharmacological therapies, their perceived costs, harms or their effectiveness, 
leading to a perceived preference for counseling. Some studies have shown that, compared with 
white tobacco users, non-whites are less likely to be screened for tobacco use or advised to quit 
by a healthcare provider [22, 23] and hence, may not be aware of all their options. Another study 
to assess ethnic minority group’s beliefs and perspectives for recommended treatment options for 
tobacco cessation found that many participants were not fully aware that medications are 
beneficial and were concerned about risks of side effects [24]. These concerns may have 
contributed to findings in the current study and may explain non-whites reported willingness-to-
try counseling over other methods. 
We found that participants with an annual income less than $30,000 were less likely to 
report willingness-to-try any medication and any counseling. This finding may be related to costs 
associated with medication and counseling especially for low-income smokers who may be 
uninsured. While the daily cost of cessation medications may be similar to the cost of cigarettes, 
these medications tend to come in weekly or monthly supply, making it unaffordable for low 
income smokers who may need to pay out of pocket [25]. This association has been mentioned in 
other studies that showed that low-income patients with chronic disease cut back on essential 
medications or are non-adherent due to cost [26, 27]. Removal of the cost barrier or the offer of 
free treatment may increase preference and hence, utilization of pharmacotherapy for tobacco 
cessation among low-income patients [28]. 
Although we found that participants with lower levels of education were less likely to 
indicate a  willingness-to-try any counseling, other studies have shown mixed results, indicating 
a positive, negative or non-significant association between low education and participation in 
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counseling.[11,29,30,31] Our findings could also be the result of the low likelihood of people 
with low educational status to receive smoking cessation advice [23,32] and hence may not be 
aware of counseling as an option.  
Tobacco use characteristics seem to play a role in willingness-to-try different cessation 
methods. Participants with a high level of nicotine dependence were more likely to report a 
willingness-to-try any evidence-based method and less likely to report willingness-to-try to quit 
cold turkey. This is similar to findings by Zhu et al who found that heavy smokers were twice as 
likely to seek assistance as light smokers. In this study, the assistance involved both evidence-
based and non-evidenced-based methods such as self-help materials [11]. The fact that those 
with high level of nicotine dependence are less likely to quit cold turkey may stem from previous 
failed attempts to quit without assistance or concerns that their severity of nicotine dependence 
may make it challenging to quit independently.  
In addition, participants with history of previous quit attempts were more likely to report 
willingness-to-try any evidence-based method. A similar study that assessed preferences for 
future quit attempts showed that a history of previous quit attempt with medications was 
associated with interest in pharmacotherapy for future quit attempts [33]. Another showed that 
smokers tend to use same cessation methods that they tried at their baseline quit attempt [34]. It 
is unclear if participants in our study reported willingness-to-try evidence-based methods based 
on cessation methods used during previous quit attempts. 
Our study also showed that dual users were more willing to report a willingness-to-try 
both evidence and non-evidenced-based methods compared with tobacco cigarette only users. 
The significant difference noted between the two groups suggests that dual users are willing to 
try any method in an attempt to stop smoking. This is similar to findings from various studies 
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have shown that e-cigarette users are likely to attempt to quit [35, 36], although this may not 
translate to successful quitting. 
Limitations of this study include its cross-sectional design and restriction to those able to 
complete an online survey. Since the study was on volunteer participants, the findings may not 
be applicable to the general population. The cross-sectional nature also limits the ability to 
explore causality and to capture other factors that may affect responses of participants. 
Participants were not asked about their knowledge of smoking cessation methods and may not 
have been aware of all methods or their efficacy, which may have affected their report of 
willingness-to-try different methods. Another limitation is the reliance of self-reported 
information about smoking status and habit, which may not reflect true characteristics. Our 
findings are reflective of participants’ willingness-to-try different methods and may not correlate 
with actual choices. Responses to questions may have been affected by participants’ recall bias. 
Furthermore, we were unable to analyze for differences between minority race and ethnicities 
due to the limited number of non-white or Hispanic individuals in our sample. 
 
Conclusion 
Despite improvement in the availability of interventions for smoking cessation, success rate is 
still suboptimal. To close this gap, efforts have been made to increase access to evidence-based 
methods of cessation but some methods remain preferred over others. Findings of this study 
highlight preferred methods for smoking cessation based on sociodemographics and level of 
nicotine dependence. The implication is that medical providers and those involved in the 
provision of tobacco cessation programs need to be mindful that individuals can differ in their 
preference for a smoking cessation method based on factors such as sociodemographics and 
nicotine dependence. In addition, increased education on evidenced-based tobacco cessation 
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methods for smokers trying to quit will be beneficial. Further studies to evaluate methods 
actually used by former tobacco users of different sociodemographics and level of nicotine 
dependence will be helpful and may aid in the development of targeted therapies for patients to 
















Table 1: Demographic Characteristics, N=562 
Characteristics Total, N (%) or mean (SD) 
Age, years 47 (20) 
Female 263 (47%) 
White 460 (82%) 
Hispanic or Latino/a                           61 (11%) 
High school or less 135 (24%) 
<$30,000 annual income 134 (24%) 
Days of tobacco use in past 30-day 
period 
21 (11) 
21 or more cigarettes/day 67 (12%) 
Time to smoke after wake   
5 minutes or less 78 (14%) 
6-30 minutes 237 (42%) 
31-60 minutes 83 (15%) 
>60 minutes 164 (29%) 
History of quit attempts 466 (83%) 
Current ENDS use 269 (48%) 
ENDS =  electronic nicotine delivery system; N = sample size; SD = 
















Table 2: Association between baseline characteristics and willingness-to-try cessation methods among tobacco 













try “cold turkey” 






Adjusted RR (95% 
CI) 
Age - 0.99 (0.99, 1.00) 1.0 (0.99, 1.00) 0.99 (0.99, 1.00) 
Gender (female vs. 
male) 
- - 1.07 (0.98, 1.16) - 
 Race (non-white 
vs. white) 
- 1.32 (1.14, 1.52) - 1.00 (0.88, 1.13) 
Hispanic (Yes vs. 
No) 
- - - 0.95 (0.82, 1.11) 
Education (HS or 
less vs. Some 
college or higher) 




0.84 (0.73, 0.98) 0.82 (0.67, 0.99) 0.93 (0.82, 1.04) - 
Heaviness of 
Smoking Index 
score (High vs 
Low/Medium) 
1.11 (1.07, 1.15) 1.06 (1.02, 1.12) 1.07 (1.04, 1.10) 0.90 (0.87, 0.94) 
Ever tried to quit 
(Yes vs. No) 
1.30 (1.06, 1.58) 1.36 (1.07, 1.72) 1.31 (1.10, 1.56) 1.15 (0.98, 1.35) 
Current ENDS use 
(Yes vs. No) 
- - 1.05 (0.95, 1.15) - 
 











Table 3. Willingness-to-try tobacco cessation methods, n (%) 














Nicotine containing products 329 (58%) 161 (55%) 168 (62%) 0.07 
Wellbutrin/Zyban 
(bupropion) 
                             197 (35%) 87 (29%) 110 (41%) 0.005 
Chantix (Varenicline) 222 (39%) 107 (36%) 115 (43%) 0.13 
Any Medication 388 (69%) 194 (66%) 194 (72%) 0.13 
          
Counseling support 
Individual counseling 221 (39%) 106 (36%) 115 (43%) 0.11 
Support group/group class 185 (33%) 80 (27%) 105 (39%) 0.003 
Telephone Quitline 147 (26%) 61 (21%) 86 (32%) 0.003 
Online program 220 (39%) 98 (33%) 122 (45%) 0.004 
Texting program 145 (26%) 60 (20%) 85 (32%) 0.003 
Any counseling support 320 (57%) 154 (53%) 166 (62%) 0.03 
Any Evidence-Based Method 
(Medication or Counseling) 
434 (77%) 214 (73%) 220 (82%) 0.01 
Non-Evidence-Based/Alternative Methods 
Complementary and Alternative Methods 
Mindfulness therapy/meditation 269 (48%) 121 (41%) 148 (55%) 0.001 
Hypnosis 256 (46%) 119 (41%) 137 (51%) 0.01 
Acupuncture 241 (43%) 114 (39%) 127 (47%) 0.05 
Any complementary and alternative 
method 
357 (63%) 171 (58%) 186 (69%) 0.008 
Other Tobacco or Nicotine Delivery Systems 
Smokeless tobacco 121 (21%) 28 (10%) 93 (35%) <0.0001 
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Electronic vaping devices (e-
cigarettes, e-hookahs, vape pens, e-
pens) 
402 (71%) 164 (56%) 238 (88%) <0.0001 
Any other tobacco or nicotine 
delivery system 
410 (73%) 167 (57%) 243 (90%) <0.0001 
Quit on My Own 
Cold turkey (pick a date and quit) 385 (68%) 191 (65%) 194 (72%) 0.07 
Cutting back gradually 467 (83%) 233 (79%) 234 (87%) 0.02 
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Appendix I: Mobile phone and Web-Based Interventions for Smoking Cessation and 
Biochemical Confirmation of Abstinence : A Limited Systematic Review 
 
INTRODUCTION 
An estimate of 1 in 6 U.S adults are current smokers, a slight improvement from 20.9% 
in 2005[1]. It is well known that smoking leads to several health consequences including 
coronary heart disease, pulmonary diseases such as chronic obstructive pulmonary disorder and 
lung cancer, stroke, miscarriages and neonatal death [2]. Several studies have shown 
improvement in success rates associated with medications and counseling, either individually or 
combined for smoking cessation[3,4]. Without any intervention, success rates can be as low as 5-
7 % [5,6]. 
A growing area of behavioral management for chronic diseases is in mobile health 
(mHealth) and web-based interventions. mHealth technology has the potential to enhance 
healthcare delivery, offers a wide range of flexibility, and benefits such as low cost and wide 
reachability [7, 8], given the large proportion of Americans with ownership or access to the 
internet and a cellular phone [9]. mHealth interventions are usually designed with increased 
convenience and patients’ accessibility to care, including the flexibility to change intervention 
content based on the response or needs of users [8,10]. These interventions create opportunities 
to tailor services and reduce barriers to care [11]. 
mHealth technology has been applied in several smoking cessation programs [12-15]. 
While they tend to be successful based on participant report of abstinence or cessation, there are 
conflicting results about the association between mHealth interventions and biochemical 
confirmation of abstinence at different time points from one’s quit date [14,16,17]. Biochemical 
confirmation is a more reliable assessment of abstinence at follow-up than self-report of 
abstinence and has been used in several studies [18]. 
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 The goal of this study is to provide a review of the evidence for mHealth and web-based 
interventions for smoking cessation and their association with biochemical confirmation of 
abstinence. The key questions (KQs) addressed here are: KQ1 - Do mHealth or web- based 
interventions for smoking cessation improve outcomes based on biochemical confirmation? and 
KQ2- does effectiveness vary by duration of intervention? 
METHODS 
Search Strategy and Data Sources 
The literature search was conducted following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed and EMBASE were 
searched from inception through February 2019 for English-language articles in scientific 
journals of human adults using MESH terms and key words relevant to mHealth intervention 
terms and tobacco cessation. Searches were further limited to randomized trials.  
Study Selection 
Studies were included if they met the eligibility criteria developed with reference to 
PICOTSS (Appendix I,Table 1). Studies in which the intervention was any mobile or web-based 
health intervention including text messaging (SMS or MMS), downloadable mobile applications 
that targeted smoking cessation were selected. Studies with any of the above interventions in 
combination with other types of activities were also included. Studies in which the comparator or 
control group included another form of mobile or web-based interventions were excluded from 
this review. There was no limit on the publication time, duration of the intervention, participants’ 
age, level of income or comorbid conditions.  
For this review, primary outcome of interest was broadly defined as objective measures 
related to smoking cessation including cotinine level and exhaled carbon monoxide levels to 
confirm abstinence. This review did not focus on subjective outcomes such as reduction in 
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number of cigarettes smoked per day, self-report of abstinence and duration of abstinence from 
smoking cessation after the intervention.  
Text Review and Data Extraction 
All titles and abstracts were evaluated against the inclusion criteria by a single reviewer. 
Full texts were assessed for eligibility and abstraction of data from relevant full texts was done by 
a single reviewer. Extraction of the following data from eligible studies was performed: 
publication date, author name, study aims and objectives, number of participants in the 
intervention and control arms, components and duration of the intervention, and relevant 
outcomes. Outcome measures were extracted at all points of measurement for studies that had 
multiple time periods for outcome measurement.  
Each included study was assessed for risk of bias using the Cochrane’s tool for risk of bias 
assessment. Studies were rated as low, high risk of bias or unclear. In the assignment of a level of 
risk of bias, studies for which there was a high confidence in the treatment effects represented in 
the results were rated as low risk. Studies in which some risks of bias were noted but not enough to 
make the results invalid and those with significant errors in the study design or analysis that likely 
had a major impact on the results were rated as having a high risk of bias. Studies were rated as 
unclear risk of bias when the risk of bias could not be ascertained based on the available data. 
 
RESULTS 
The combined search strategies yielded 493 title and abstracts, of which 111 duplicates 
were removed and 382 were screened to assess for eligibility. Sixty-eight reports were found to 
be potentially eligible and their full texts were obtained for further assessment. Out of these 
eligible reports, 5 studies met the study inclusion criteria[12,16,17,19,10]. Reasons for excluding 
27 
 
studies were primarily due to wrong outcome, wrong setting, wrong study design and wrong 
comparator. Figure 1 is a representation of the flow diagram from the screening process.  
Characteristics of studies 
The total number of participant in all studies was 1537 with samples size ranging from 14 
- 262 for intervention groups and 16 - 250 for control groups. Study duration ranged from 3 
months to 12 months for all studies except one in which the duration was dependent on the 
medication used in addition to the mHealth technology or 8 weeks for those who opted out of 
pharmacotherapy. All studies had cell phone and text messaging as the main mobile health 
device and medium of communication respectively except one that used a web-based program 
that was not cell phone specific (Appendix I, Table 2). Mobile technology was applied in several 
ways including provision of motivational messages, education and link to resources and social 
support. Most programs were interactive and centered around the chosen quit date of 
participants. Three of the studies were directed towards smoking cessation during pregnancy and 
one of these studies used the platform of an already established text message program for 
pregnant women.  
Outcomes 
The focus of this review was on the biochemical confirmation of abstinence after self-
report of cessation. Four studies assessed biochemical confirmation by examining the cotinine 
level of participants who self-reported smoking cessation at 3 months, 6 months or 12 months 
after their quit date[12,16,17,19]. Cotinine level indicating abstinence at different time points 
was set at less than or equal 13 ng/ml by 2 studies [17,19] and less than or equal to 15 ng/ml by 2 
studies[12,16]. One of the studies that set a goal or less than or equal to 15 ng/ml also set a goal 
of less than or equal 18ng/ml for participants who reported living with a smoker[16]. One study 
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used expired carbon monoxide (eCO) level to verify biochemical abstinence at 2 weeks after quit 
date[20] and set the goal of eCO at less than 5 parts per million and less than 8 parts per 
million.(Appendix I, Table 3)  
Results of one study showed a statistically significant difference in biochemically 
confirmation point prevalence abstinence between participants in the intervention group and 
control group at 3 months[12]. Although a larger percentage of participants in the intervention 
group had biochemical confirmed repeated point prevalence abstinence at 6 months follow-up 
period compared with the control group, the difference was not statistically significant[12]. For 
all other studies that used continine levels to verify 7 day or 30 day point prevalence abstinence 
at the 3 months - 12 months follow-up visit, a higher proportion of partipants in interventions 
groups who had reported abstinence were biochemical confirmed compared with those in control 
groups but no statistically significant difference was noted[16,17,19]. The study that used 
exhaled carbon monoxide levels for biochemical confirmation also reported that a higher 
proportion of those in the intervention group met the goal compared with those in the control 
group but the difference between both groups was not statistically significant[20].  
Risk of Bias Assessment 
All studies had a low risk of bias for sequence generation except one which rated as high 
risk. One study had a low risk of bias for allocation concealment. All studies except one had a 
high risk of bias for blinding of personnel and participants while all studies had a high risk of 
bias for blinding of outcome assessors. Three out of five studies received a low risk of bias for 
incomplete data while all studies received a low risk of bias for selective outcome reporting. 
Three studies received a high risk of bias for other factors, one was for contamination of 
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intervention group, another for contamination of control group with intervention and the last was 
for an underpowered study. Risk of bias assessment can be found in appendix I, Table 4.  
DISCUSSION 
This systematic review evaluates the effectiveness of mHealth and web-based interventions 
for smoking cessation with biochemical confirmation after self-reported abstinence. All 5 studies 
were randomized trials and showed consistency in terms of biochemical confirmation of abstinence 
in a larger proportion of participants who received the mHealth or web-based interventions 
compared with those in control groups. However, only one study showed a statistically significant 
difference between the intervention and control group at 3 months. Although mHealth and web-
based interventions for smoking cessation have shown significant benefits based on smokers’ self-
reports of abstinence, the association with biochemically confirmed smoking cessation has not been 
consistent. The inconsistency may be a result of other factors that may affect continine and exhaled 
carbon monoxide levels. For instance, cotinine levels may be affected by racial/ethnic differences in 
cotinine metabolism and genetic factors such as low UGT2B10 activity[21,22] and these factors may 
affect results depending on the timing of biochemical confirmation from last smoke. Biochemical 
confirmation using carbon monoxide in the blood can also be affected by the respiratory effort of 
participants[23]. Deep exhalation can lead to higher levels and low exhalation can lead to lower 
levels of carbon monoxide measured.  
This systematic review has a number of limitations. The small number of studies that met 
eligibility criteria may limit the generalizability of the findings. Another limitation is that the review 
was performed by a single reviewer who performed database searches, review of articles for 
eligibility, extraction of data and assessment of risk of bias for all included study. The addition of a 
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second reviewer, with consensus agreement, will add to the validity of the review and findings. The 
single reviewer process reduces the applicability of the findings. 
This systematic review showed mixed findings on the effectiveness of mHealth interventions 
on smoking cessation based on biochemical confirmation of abstinence. These findings are within 
the limitations of biochemical confirmatory tests and further studies done under improved and more 
reliable conditions are needed to increase the understanding of the association between mHealth 































Appendix I, Table 1: Eligibility Criteria 
Category Include Exclude 
Population Active smokers Non-smokers, ex- smokers 
Intervention Controlled trials with any mobile phone and web-based 
intervention including text messages (SMS or MMS), 
downloadable apps, use of other hand-held devices, or 
the internet for any duration of time 
 
Counseling sessions involving a 
counselor or therapist etc via 
telephone or mobile phones 
Comparators Usual care including face to face coaching, handouts, 
no intervention 
Comparative effectiveness studies 
or studies in which both 
intervention and control groups 
had any form of mobile phone or 
web-based intervention.  
Outcome(s) Objective measures: biochemical confirmation of 
abstinence such as cotinine level or expired carbon 
monoxide level 
All other outcomes, including self-
reported smoking cessation 
Timing  All years N/A 
Setting Studies performed in the United States Other countries 












Appendix I, Table 2. Baseline characteristics of studies 
Author, year Aim Sample size Intervention Comparator Duration of study  








Control - 241 
Intervention - 
262 
Text2Quit - text 
message, email and 
web-portal 




Abroms et al, 
2017 




aimed at pregnant 
women 




advice and tips on 
how to quit, social 
support, 
information on 
harms of smoking 









date and baby’s 
due date 
A single text 
message that 
provided a 










Abroms et al, 
2017  








Control = 250 
Intervention = 
247 
1 - 8 text messages 
per day with 
highest number on 




taper over time and 
stop at 3 months. 
Between 1 month 
prior to baby’s 
arrival and 6 
months after, 





text keywords to 
the program for 
additional support 






Calhoun et al, 
2016 
To compare the 
impact and cost-
effectiveness of an 




membership to the 









program paired with 
a telemedicine clinic 
to an assisted 
referral to specialty 
smoking cessation 
clinic -based care 






support that is 
personalized and 
based on readiness 
to quit. Provision 






















renewals sent by 
mail  
Forinash et al, 
2018 
To evaluate the 




pregnant women in 
addition to standard 
of care          
Control = 16 
Intervention = 
14 
Usual care plus 
motivational text 
messages focused 
on pregnancy and 
smoking cessation, 
starting 3 days 
prior to quit date, 
then 1 day prior, 
on the quit date 
and tapering until 
delivery.  
Pharmacy-driven 




phone calls to 
patients within 3 
days after quit 
date and weekly 
for 2 weeks. 
Through completion 
of pharmacotherapy 
or 8 weeks for those 





























Appendix I, Table 3. Effect estimates for outcome 
Study Biochemical Outcome Results 
Abroms et al, 2014 Biochemically confirmed 
repeated point prevalent 
abstinence i.e. not 
smoking in the past 30 
days at 3 months and 6 
months follow-up and 
cotinine level of 
</=15ng/ml at 6 months 
Biochemically confirmed repeated point prevalence 
abstinence  
Intervention (%) = 11.1% 
Control (%) = 5.0% 
RR (95% CI) = 2.22 (1.16, 4.26) 
 
Biochemically confirmed repeated point prevalence 
abstinence at 6 month follow-up 
Intervention (%) = 15.7% 
Control (%) = 11.2% 
RR (95% CI) = 1.40 (0.89, 2.20) 
 
Abroms et al, 2017 7 day biochemically 
confirmed point 
prevalence abstinence at 
3 months i.e self report 
of no smoking in past 7 
days on 3 month survey 
and a cotinine level of 
</=13 ng/ml.  
Biochemically confirmed 7 day point prevalence abstinence 
Intervention (%) =14.55% 
Control (%) = 9.09 % 
 
Abroms et al, 2017 7 day and 30 day 
biochemically confirmed 
PPA at 3 months follow-
up i.e. self-report of no 
smoking in past 7 or 30 
days and cotinine level < 
13 ng/ml 
Biochemically confirmed 7-day point prevalence abstinence 
 
Intervention (%) = 39 (15.60)  
Control (%) = 27 (10.93)  
RR ( 95% CI) = 1.51 (0.89–2.55)  
(Missing data imputed to indicate smoking ) 
 
Intervention (%) = 39 (19.90)  
Control (%) = 27 (13.04)  
RR( 95% CI) = 1.53 (0.97–2.39) 
(Only complete cases) 
 
Biochemically confirmed 30-day point prevalence abstinence 
 
Intervention (%) = 32 (12.80) 
Control (%) = 26 (10.53)  
RR( 95% CI) = 1.12 (0.83–1.52)  
(Missing data imputed to indicate smoking ) 
 
Intervention (%) = 32 (16.33) 
Control (%) = 26 (12.56)  
RR(95%CI) = 1.30 (0.81–2.10)  
(Only complete cases) 
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Calhoun et al, 2016 Biochemical 
confirmation of 
abstinence at 12 month 
follow-up - cotinine level 
of </=15 ng/ml or </=18 
ng/ml if the participant 




Intervention (%) = 5.4% 
Control (%) = 3.5% 
 
*missing data and untestable samples included in analyses as 
smoking 
Forinash et al, 2018 Verification by exhaled 
carbon monoxide level 2 
weeks after quit date 
2 weeks cessation with eCO < 8 ppm  
Intervention - 57.1% 
Control = 31.3% 
OR( 95% CI ) = 2.93 (0.66, 13.09) 
 
2 week cessation with eCO < 5 ppm 
Intervention - 35.7% 
Control = 12.5% 
OR ( 95% CI ) = 3.89 (0.62, 24.52) 
 








Appendix I, Table 4: Risk of Bias Assessment 


















Low High High High Low Low Unclear 
Abroms et 
al, 2017 
High High High High Low Low High * 
Abroms et 
al2, 2017  
Low High High High Low Low High ** 
Calhoun et 
al, 2016 
Low Low Low High High Low Low 
Forinash et 
al, 2018 
Low Unclear High High High Low High*** 
* 2 participants from intervention group received a component of the control group 
** Some level of contamination. At 3 month survey, 6 participants in control group had used the Text4baby for smoking 
cessation  
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